文献速递介入腹部USDSA

凡德他尼洗脱不透射线微球:在兔肝癌模型中的药代动力学、安全性和疗效

Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.
PubMed 文献 · Radiology · 2019-10-15

在60只VX2肝肿瘤兔中比较凡德他尼洗脱不透射线微球(VERB)与空白不透射线微球、动脉内凡德他尼混悬液及未治疗组的药代动力学、安全性和疗效。VERB组血浆凡德他尼浓度低于混悬液组(P < .01),3周时肿瘤生长低于空白微球组和混悬液组(中位值+114%、+192%、+466%),微球沉积量和肿瘤药物浓度分别是3天和3周肿瘤生长的预测因素。

要点

  • VERB动脉化疗栓塞在兔肝癌模型中显示药代动力学优势,肿瘤内药物浓度高于动脉内给药。
  • 3周时VERB组肿瘤生长中位值+114%,低于空白微球组+192%和混悬液组+466%。
  • 肿瘤内微球体积是3天肿瘤生长的预测因素(P = .03),肿瘤药物浓度是3周肿瘤生长的预测因素(P = .04)。

核心结论

  • 凡德他尼洗脱不透射线微球化疗栓塞在临床前肝癌模型中显示优于动脉内给药的药代动力学优势;肿瘤内高微球沉积和高凡德他尼浓度带来更强的抗肿瘤效果。

研究设计与样本

  • 2015年4月至2016年3月,60只携带VX2肝肿瘤的新西兰白兔随机接受不同剂量VERB、空白不透射线微球(ROB)、动脉内凡德他尼混悬液(VS)治疗或未治疗;评估血浆药物浓度和超声肿瘤生长,3天或3周后处死,行X线微球分布评估、组织学检查肿瘤活力和药物组织浓度测定。

关键影像表现/征象

  • X线成像评估微球分布,组织学检查评估肿瘤活力;VERB组3天肿瘤活力为3%,ROB组为18%,VS组为38%,3周时组间无显著差异。
  • 3周时肿瘤生长中位值:VERB组+114%,ROB组+192%,VS组+466%。
  • 3天时肿瘤内凡德他尼浓度中位值VERB组29.2 ng/mg,VS组2.74 ng/mg(P = .48)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Transarterial chemoembolization with cytotoxic drugs is standard treatment for unresectable intermediate-stage hepatocellular carcinoma but achieves suboptimal outcomes because of hypoxic stress and the production of detrimental proangiogenic factors. An alternative approach using radiopaque embolization beads loaded with the antiangiogenic drug vandetanib may provide improved anticancer efficacy. Purpose To evaluate the pharmacokinetics, safety, and efficacy of vandetanib-eluting radiopaque bead (VERB) chemoembolization of rabbit liver tumors. Materials and Methods Between April 2015 and March 2016, 60 New Zealand white rabbits with VX2 liver tumors were randomly treated with VERBs at different doses, with nonloaded radiopaque beads (ROBs), or with intra-arterial vandetanib suspension (VS) or were not treated. Vandetanib plasma concentration and tumor growth at US were evaluated. Animals were euthanized after 3 days or 3 weeks. Assessment included bead distribution at x-ray imaging and histologic examination, tumor viability at histologic examination, and vandetanib tissue concentration. Group comparison analysis (Mann-Whitney, Kruskal-Wallis, and χ2 tests) and predictive factor analysis for tumor growth and viability were performed. Results Vandetanib plasma concentration was lower with VERBs than with VS (P < .01), while concentration in tumor was higher for VERBs (than for VS) at 3 days (median, 29.2 vs 2.74 ng/mg; P = .48). Tumor growth was lower with VERBs than with ROBs and with VS at both time points, with median values of +114%, +192%, and +466% at 3 weeks, respectively. Tumor viability was lower at 3 days for VERBs than for ROBs and for VS (3%, 18%, and 38%, respectively) but was not significantly different at 3 weeks. The volume of bead in tumor was a significant predictive factor for lower tumor growth in multivariable analysis at 3 days (P = .03). Drug tumor concentration was a significant predictive factor for lower tumor growth at 3 weeks (P = .04). Conclusion Vandetanib-eluting radiopaque bead chemoembolization showed a pharmacokinetic advantage over intra-arterial drug administration in a preclinical model of liver cancer. High deposition of beads and high vandetanib concentration in tumor led to stronger antitumor effects. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Kim and Van den Abbeele in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Duran R, Namur J, Pascale F, et al. Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. Radiology. 2019. PMID: 31617791. doi:10.1148/radiol.2019190305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。